Repligen Corporation (NASDAQ: RGEN) Stock Competitors & Peer Comparison
See RGEN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RGEN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGEN | $166.15 | -1.71% | 9.4B | 92.31 | $1.80 | N/A |
| ISRG | $391.18 | +0.22% | 138.2B | 40.66 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.05% |
| BDX | $180.77 | -1.43% | 50.2B | 14.01 | $13.00 | +2.05% |
| MDLN | $34.12 | -2.18% | 28.9B | 25.00 | $1.36 | N/A |
| WST | $346.59 | -0.01% | 24.4B | 43.50 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.45 | +0.73% | 15.1B | 12.31 | $7.10 | N/A |
| COO | $75.76 | +0.88% | 14.8B | 16.61 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.05% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RGEN vs ISRG Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ISRG has a market cap of 138.2B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ISRG trades at $391.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ISRG's P/E ratio is 40.66. In terms of profitability, RGEN's ROE is +0.02%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, RGEN is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RGEN vs BDXA Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
RGEN vs BDX Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BDX has a market cap of 50.2B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BDX trades at $180.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BDX's P/E ratio is 14.01. In terms of profitability, RGEN's ROE is +0.02%, compared to BDX's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
RGEN vs MDLN Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, MDLN has a market cap of 28.9B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while MDLN trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas MDLN's P/E ratio is 25.00. In terms of profitability, RGEN's ROE is +0.02%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RGEN is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RGEN vs WST Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, WST has a market cap of 24.4B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while WST trades at $346.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas WST's P/E ratio is 43.50. In terms of profitability, RGEN's ROE is +0.02%, compared to WST's ROE of +0.19%. Regarding short-term risk, RGEN is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RGEN vs HOLX Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGEN's ROE is +0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGEN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
RGEN vs SOLV Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, SOLV has a market cap of 15.1B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while SOLV trades at $87.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas SOLV's P/E ratio is 12.31. In terms of profitability, RGEN's ROE is +0.02%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, RGEN is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RGEN vs COO Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, COO has a market cap of 14.8B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while COO trades at $75.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas COO's P/E ratio is 16.61. In terms of profitability, RGEN's ROE is +0.02%, compared to COO's ROE of +0.03%. Regarding short-term risk, RGEN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RGEN vs BDXB Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGEN's ROE is +0.02%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RGEN vs BAX Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BAX has a market cap of 13.4B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BAX trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BAX's P/E ratio is 12.46. In terms of profitability, RGEN's ROE is +0.02%, compared to BAX's ROE of -0.17%. Regarding short-term risk, RGEN is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
RGEN vs AVTR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, AVTR has a market cap of 9B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while AVTR trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas AVTR's P/E ratio is 15.72. In terms of profitability, RGEN's ROE is +0.02%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGEN is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
RGEN vs ATR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ATR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ATR's P/E ratio is 23.03. In terms of profitability, RGEN's ROE is +0.02%, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RGEN vs BLCO Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BLCO trades at $17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BLCO's P/E ratio is 26.12. In terms of profitability, RGEN's ROE is +0.02%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGEN is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
RGEN vs TFX Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while TFX trades at $131.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas TFX's P/E ratio is 15.08. In terms of profitability, RGEN's ROE is +0.02%, compared to TFX's ROE of -0.32%. Regarding short-term risk, RGEN is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RGEN vs STVN Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while STVN trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas STVN's P/E ratio is 32.13. In terms of profitability, RGEN's ROE is +0.02%, compared to STVN's ROE of +0.09%. Regarding short-term risk, RGEN is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RGEN vs MMSI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while MMSI trades at $89.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas MMSI's P/E ratio is 22.83. In terms of profitability, RGEN's ROE is +0.02%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGEN is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RGEN vs ICUI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ICUI trades at $183.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ICUI's P/E ratio is 22.94. In terms of profitability, RGEN's ROE is +0.02%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, RGEN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
RGEN vs NVST Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NVST trades at $27.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NVST's P/E ratio is 18.93. In terms of profitability, RGEN's ROE is +0.02%, compared to NVST's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RGEN vs PLSE Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, PLSE has a market cap of 3.2B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while PLSE trades at $46.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas PLSE's P/E ratio is -38.98. In terms of profitability, RGEN's ROE is +0.02%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, RGEN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RGEN vs ATRC Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ATRC has a market cap of 2.3B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ATRC trades at $45.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ATRC's P/E ratio is 1421.12. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RGEN is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RGEN vs XRAY Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while XRAY trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas XRAY's P/E ratio is 7.77. In terms of profitability, RGEN's ROE is +0.02%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, RGEN is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RGEN vs LMAT Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while LMAT trades at $81.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas LMAT's P/E ratio is 29.97. In terms of profitability, RGEN's ROE is +0.02%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGEN is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RGEN vs BLFS Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while BLFS trades at $34.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas BLFS's P/E ratio is -167.73. In terms of profitability, RGEN's ROE is +0.02%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RGEN is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check BLFS's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RGEN vs KMTS Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while KMTS trades at $27.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas KMTS's P/E ratio is -11.83. In terms of profitability, RGEN's ROE is +0.02%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, RGEN is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check KMTS's competition here
Azenta, Inc. (NASDAQ: AZTA)
RGEN vs AZTA Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while AZTA trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas AZTA's P/E ratio is 79.95. In terms of profitability, RGEN's ROE is +0.02%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RGEN is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AZTA's competition here
STAAR Surgical Company (NASDAQ: STAA)
RGEN vs STAA Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while STAA trades at $24.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas STAA's P/E ratio is 43.23. In terms of profitability, RGEN's ROE is +0.02%, compared to STAA's ROE of +0.01%. Regarding short-term risk, RGEN is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
RGEN vs QDEL Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, QDEL has a market cap of 915.8M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while QDEL trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas QDEL's P/E ratio is 10.02. In terms of profitability, RGEN's ROE is +0.02%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, RGEN is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
RGEN vs ATRI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGEN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RGEN vs ANGO Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ANGO has a market cap of 653.9M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ANGO trades at $15.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ANGO's P/E ratio is -40.56. In terms of profitability, RGEN's ROE is +0.02%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RGEN is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RGEN vs NNNN Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NNNN has a market cap of 366.5M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NNNN trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NNNN's P/E ratio is 120.66. In terms of profitability, RGEN's ROE is +0.02%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGEN is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RGEN vs SMTI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, SMTI has a market cap of 314.1M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while SMTI trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas SMTI's P/E ratio is -569.50. In terms of profitability, RGEN's ROE is +0.02%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RGEN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RGEN vs OSUR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, OSUR has a market cap of 258.2M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while OSUR trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas OSUR's P/E ratio is -6.82. In terms of profitability, RGEN's ROE is +0.02%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RGEN is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
RGEN vs INFU Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, INFU has a market cap of 246.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while INFU trades at $12.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas INFU's P/E ratio is 29.78. In terms of profitability, RGEN's ROE is +0.02%, compared to INFU's ROE of +0.15%. Regarding short-term risk, RGEN is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RGEN vs UTMD Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, UTMD has a market cap of 229.3M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while UTMD trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas UTMD's P/E ratio is 21.30. In terms of profitability, RGEN's ROE is +0.02%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGEN is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RGEN vs PDEX Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while PDEX trades at $66.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas PDEX's P/E ratio is 23.55. In terms of profitability, RGEN's ROE is +0.02%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, RGEN is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RGEN vs KRMD Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, KRMD has a market cap of 153M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while KRMD trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas KRMD's P/E ratio is -83.25. In terms of profitability, RGEN's ROE is +0.02%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RGEN is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
RGEN vs MBOT Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, MBOT has a market cap of 67M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while MBOT trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas MBOT's P/E ratio is -5.65. In terms of profitability, RGEN's ROE is +0.02%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, RGEN is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RGEN vs AKYA Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGEN's ROE is +0.02%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGEN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
RGEN vs DXR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, DXR has a market cap of 57.2M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while DXR trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas DXR's P/E ratio is 25.63. In terms of profitability, RGEN's ROE is +0.02%, compared to DXR's ROE of +0.22%. Regarding short-term risk, RGEN is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
RGEN vs STSS Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to STSS's ROE of -1.54%. Regarding short-term risk, RGEN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RGEN vs OMIC Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGEN's ROE is +0.02%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGEN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RGEN vs IGAP Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGEN's ROE is +0.02%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RGEN is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
RGEN vs NEPH Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NEPH has a market cap of 49.8M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NEPH trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NEPH's P/E ratio is 76.50. In terms of profitability, RGEN's ROE is +0.02%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RGEN is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RGEN vs POCI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, POCI has a market cap of 47.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while POCI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas POCI's P/E ratio is -6.02. In terms of profitability, RGEN's ROE is +0.02%, compared to POCI's ROE of -0.37%. Regarding short-term risk, RGEN is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RGEN vs MLSS Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, MLSS has a market cap of 43.3M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while MLSS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas MLSS's P/E ratio is -8.16. In terms of profitability, RGEN's ROE is +0.02%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RGEN is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RGEN vs HBIO Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, HBIO has a market cap of 31.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while HBIO trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas HBIO's P/E ratio is -19.36. In terms of profitability, RGEN's ROE is +0.02%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RGEN is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RGEN vs SDC Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGEN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
RGEN vs IVC Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGEN's ROE is +0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGEN is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check IVC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RGEN vs ZJYL Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ZJYL has a market cap of 24.1M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ZJYL trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ZJYL's P/E ratio is 19.25. In terms of profitability, RGEN's ROE is +0.02%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGEN is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check ZJYL's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RGEN vs RVP Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, RVP has a market cap of 21.7M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas RVP's P/E ratio is -2.20. In terms of profitability, RGEN's ROE is +0.02%, compared to RVP's ROE of -0.05%. Regarding short-term risk, RGEN is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
RGEN vs RGNT Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, RGNT has a market cap of 14M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while RGNT trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas RGNT's P/E ratio is -0.08. In terms of profitability, RGEN's ROE is +0.02%, compared to RGNT's ROE of N/A. Regarding short-term risk, RGEN is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
RGEN vs FEMY Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, FEMY has a market cap of 6.6M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while FEMY trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas FEMY's P/E ratio is -6.08. In terms of profitability, RGEN's ROE is +0.02%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RGEN is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RGEN vs NSTG Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGEN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NSTG's competition here
Lucyd, Inc (NASDAQ: LUCY)
RGEN vs LUCY Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, LUCY has a market cap of 4.5M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while LUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas LUCY's P/E ratio is -0.43. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RGEN is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RGEN vs POAI Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas POAI's P/E ratio is -0.03. In terms of profitability, RGEN's ROE is +0.02%, compared to POAI's ROE of -21.19%. Regarding short-term risk, RGEN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RGEN vs NXGL Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NXGL trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NXGL's P/E ratio is -0.55. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NXGL's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
RGEN vs GCTK Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, GCTK has a market cap of 2.6M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while GCTK trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas GCTK's P/E ratio is -0.02. In terms of profitability, RGEN's ROE is +0.02%, compared to GCTK's ROE of -21.36%. Regarding short-term risk, RGEN is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RGEN vs MHUA Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGEN's ROE is +0.02%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGEN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RGEN vs GMVD Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RGEN vs GMVDW Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGEN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RGEN vs NXGLW Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, NXGLW has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas NXGLW's P/E ratio is -0.05. In terms of profitability, RGEN's ROE is +0.02%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RGEN is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check NXGLW's competition here
Avinger, Inc. (NASDAQ: AVGR)
RGEN vs AVGR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGEN's ROE is +0.02%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGEN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RGEN vs LUCYW Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RGEN's ROE is +0.02%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RGEN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGEN.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
RGEN vs APR Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, APR has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas APR's P/E ratio is 22.59. In terms of profitability, RGEN's ROE is +0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, RGEN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RGEN vs HRC Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGEN's ROE is +0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGEN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
RGEN vs IIN Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGEN's ROE is +0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGEN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
RGEN vs ALOG Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGEN's ROE is +0.02%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGEN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
RGEN vs IVTY Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGEN's ROE is +0.02%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGEN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RGEN vs ATRS Comparison August 2026
Repligen Corporation (NASDAQ: RGEN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGEN stands at 9.4B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGEN is priced at $166.15 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGEN currently has a P/E ratio of 92.31, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGEN's ROE is +0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGEN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGEN.Check ATRS's competition here